Cowen Remains Bullish on XOMA (XOMA) Ahead of EYEGUARD-B Data

Cowen maintains an Outperform rating on XOMA, Ltd. (NASDAQ: XOMA), ahead of EYEGUARD-B trial data. Analyst Phil Nadeau says that consultants believe EYEGUARD-B is “likely” to hit its primary endpoint. Data is expected to be released mid-July.

Nadeau commented, "In advance of the mid-July data release from gevokizumab’s EYEGUARD-B trial, we have discussed its prospects with four uveitis physician KOLs. Our consultants believe that EYEGUARD-B is “likely” to hit its primary endpoint. All of our consultants think that positive results in Behcet's will derisk the other Ph. IIIs in NIU. We maintain Outperform."

For an analyst ratings summary and ratings history on XOMA, Ltd. click here. For more ratings news on XOMA, Ltd. click here.

Shares of XOMA, Ltd. closed at $3.72 yesterday.

You May Also Be Interested In

• Abbott Labs (ABT) PT Raised to $135 at TD Cowen
• Advance Auto Parts (AAP) PT Lowered to $45 at TD Cowen
• HSBC Downgrades China Power International (2380:HK) (CPWIF) to Hold